Comparison of serum cytokine levels between dogs with multicentric lymphoma and healthy dogs

Calvalido, Jérôme; Wood, Geoffrey A.; Mutsaers, Anthony J.; Wood, Darren; Sears, William; Woods, J. Paul

doi:10.1016/j.vetimm.2016.10.009

Cited by 31 publications

(44 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is also possible the multiplex assay that was employed was relatively insensitive to small changes in cytokine concentrations. Although this assay has been widely used, some analyte concentrations are frequently below the limits of detection, as was the case in the present study (Figure ) . A recent study attempted to determine normal reference ranges for the 13 cytokines measured in this assay and compared the cytokine concentrations in dogs with sepsis to those in dogs with immune‐mediated hemolytic anemia (IMHA) .…”

Section: Discussionmentioning

confidence: 91%

“…Other groups have also found that CCL2 is prognostic in IMHA, lymphoma, and babesiosis . CCL2 is also a potential diagnostic marker in dogs with neoplasia and is a marker of disease severity in myxomatous mitral valve disease, diabetes mellitus, polyarthropathy, and pulmonary fibrosis . Further work is needed to identify the key stimuli for CCL2 release in dogs and to determine why CCL2 is strongly associated with disease severity and outcome in dogs with diverse disease processes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the host cytokine response in dogs with sepsis and noninfectious systemic inflammatory response syndrome

Goggs

Letendre

2019

J Vet Emergen Crit Care

View full text Add to dashboard Cite

Objective: To quantify plasma cytokine concentrations in dogs with sepsis and noninfectious systemic inflammation and to evaluate the association between plasma cytokines and outcome in dogs with sepsis.Design: Prospective, observational cohort study. Setting: University teaching hospital.Animals: Forty-five dogs with sepsis, 10 dogs with noninfectious systemic inflammation (nSIRS), and 15 healthy controls were consecutively enrolled from June 2015 to February 2016 and followed to hospital discharge. Dogs with sepsis satisfied ≥2 SIRS criteria and had a documented or highly suspected bacterial infection. Dogs with nSIRS satisfied ≥2 SIRS criteria but had no evidence of infection. Dogs <3 kg and those with documented coagulopathy were excluded.Interventions: Measurement of inflammatory cytokines and high-mobility group box-1 (HMGB-1) was performed on each group. Measurements and Main Results:High-mobility group box-1 concentrations were analyzed by ELISA. Plasma concentrations of 13 cytokines were measured in singlet using multiplex magnetic bead assays. Kruskal-Wallis with Dunn's multiple comparison tests were used to compare biomarker concentrations between groups. Mann-Whitney U-tests were used to compare biomarker concentrations between survivors and nonsurvivors. Associations between biomarkers were evaluated using Spearman's correlation coefficients. Independent outcome predictors were identified using multivariable logistic regression. Alpha was set at 0.05. Concentrations of interleukin (IL)-6, C-X-C motif chemokine (CXCL)-8, keratinocyte-derived chemokine (KC)-like, C-C motif chemokine ligand 2 (CCL2), and HMGB-1 were significantly greater in dogs with sepsis versus healthy controls (all P ≤ 0.034). In dogs with sepsis, only CCL2 was independently associated with survival (odds ratio [OR] 0.996, 95% CI 0.993-0.999, P = 0.004). A cut-off of 385 pg/mL for CCL2 was 80% sensitive and 91.4% specific for nonsurvival (area under the ROC curve [AUROC] 0.866). Conclusions:Dogs with sepsis have significantly increased concentrations of HMGB-1 and inflammatory cytokines, including IL-6, CXCL8, and KC-like. Increased CCL2 concentration is a negative prognostic indicator in dogs with sepsis. These findings should be confirmed using duplicate analyses in larger, distinct populations of dogs with sepsis before applying them to clinical patients. K E Y W O R D Scanine, CCL2, HMGB-1, outcome, SIRS

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Evaluation of the host cytokine response in dogs with sepsis and noninfectious systemic inflammatory response syndrome

Goggs

Letendre

2019

J Vet Emergen Crit Care

View full text Add to dashboard Cite

show abstract

“…It has not been studied previously in dogs with liver disease, but CCL2 production by canine hepatocytes was inhibited in vitro by the commercially available liver protectant, silybin . Increased serum CCL2 concentrations also have been found in critically ill dogs, and in those with lymphoma, histiocytic sarcoma, pulmonary fibrosis, congestive heart failure, and immune‐mediated hemolytic anemia . Thus, this marker is not specific to dogs with primary liver disease.…”

Section: Discussionmentioning

confidence: 99%

“…39 Increased serum CCL2 concentrations also have been found in critically ill dogs, 20 and in those with lymphoma, histiocytic sarcoma, pulmonary fibrosis, congestive heart failure, and immune-mediated hemolytic anemia. 22,27,28,40,41 Thus, this marker is not specific to dogs with primary liver disease. Based on our data, individual measurements of serum CCL2 cannot be used as a reliable marker of necroinflammatory activity in dogs with clinical evidence of liver disease.…”

Section: Biomarker Datamentioning

confidence: 99%

Evaluation of potential serum biomarkers of hepatic fibrosis and necroinflammatory activity in dogs with liver disease

Raghu

Ekena

Cullen

et al. 2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundSerum interleukin 6 (IL‐6), chemokine ligand 2 (CCL2), C‐reactive protein (CRP), and the ratio of aspartate transaminase to alanine transaminase (AST:ALT) have been correlated with fibrosis and necroinflammatory activity in humans with various hepatopathies.Hypothesis/ObjectivesTo determine whether increases in serum IL‐6, CCL2, CRP, or AST:ALT were associated with moderate to severe fibrosis or necroinflammatory activity in dogs with various hepatopathies.AnimalsForty‐four client‐owned dogs with clinical evidence of liver disease and 10 healthy purpose‐bred dogs, all undergoing liver biopsies by laparoscopy or laparotomy.MethodsMeasurement of serum IL‐6, CCL2, CRP, AST, and ALT before scheduled liver biopsy and evaluation of liver histopathology using the METAVIR scoring system used in human medicine, blinded to clinical presentation.ResultsMedian serum IL‐6 was approximately twice as high in dogs with high fibrosis scores (15.5 pg/mL; range, 1.4 to 235 pg/mL) compared to dogs with low fibrosis scores (7.6 pg/mL; range, 1.4 to 148.1 pg/mL), with marginal significance (P = .05). Median serum CCL2 was significantly higher in dogs with active necroinflammation (444 pg/mL; range, 144 to 896 pg/mL) compared to dogs without detectable necroinflammation (326 pg/mL; range, 59 to 1692 pg/mL; P = .008), but with considerable overlap between groups. Neither serum CRP nor AST:ALT ratios were significantly different based on fibrosis or necroinflammatory scores.Conclusions and Clinical ImportanceBecause of substantial variability among dogs, single measurements of IL‐6 and CCL2 have limited diagnostic utility for identifying fibrosis or necroinflammation, respectively, in dogs with various chronic liver diseases. The value of these biomarkers should be explored further in monitoring response to treatment in individual dogs with chronic hepatopathies.

show abstract

“…en caninos los linfomas son las neoplasias hematopoyé-ticas más comunes, con prevalencias entre el 7 y el 24% del total de neoplasias. de ellas, entre 60 y 80% son de origen celular B y entre el 10 y el 38% son de origen celular T (Calvalido et al 2016).…”

Section: Introductionunclassified

Presencia del marcador lmp-1 del virus epstein barr en linfomas de caninos

Veloza

Collazos

Olaya

et al. 2017

Rev. Med. Vet. Zoot.

View full text Add to dashboard Cite

rEsumEN el virus epstein-Barr (ebv) es un virus de alta prevalencia en humanos que se asocia con tumores de la línea linfoide B. en caninos se dispone de pocos reportes sobre la presencia del ebv y su rol en esta especie. el objetivo del presente estudio fue determinar la presencia de la proteína latente de membrana del ebv (lmp-1) en tejidos obtenidos de 20 linfomas de caninos cuyo diagnóstico se había realizado durante un periodo de 10 años, entre 2004 y 2014. Los linfomas se reclasificaron mediante las nuevas clasificaciones histopatológicas para linfomas y se sometieron a inmunohistoquímica (iHQ) con los anticuerpos anti-cd79a, anti-cd3, anticuerpos específicos para linfocitos B y T, además de un anti-lmp-1 como marcador de la presencia del ebv. se encontró que el linfoma más común fue el linfoma nodal de zona T con un 75% de los casos. al realizar la inmunomarcación se encontraron 18 casos positivos a cd3, 2 casos positivos a cd79a y 6 casos positivos a lmp-1, lo que representa el 30% de positividad del ebv en linfomas. el análisis Ji cuadrado demostró significancia estadística entre la presencia del virus y la presencia del linfoma lo que sugiere, no solamente que el virus está circulando en la población canina, sino que además puede tener relación con la ocurrencia de esta neoplasia. Con relación a las variables demográficas, sólo en la raza Golden retriever se demostró relación con la presencia del linfoma, pero no con la presencia del virus.

show abstract

Comparison of serum cytokine levels between dogs with multicentric lymphoma and healthy dogs

Cited by 31 publications

References 52 publications

Evaluation of the host cytokine response in dogs with sepsis and noninfectious systemic inflammatory response syndrome

Evaluation of the host cytokine response in dogs with sepsis and noninfectious systemic inflammatory response syndrome

Evaluation of potential serum biomarkers of hepatic fibrosis and necroinflammatory activity in dogs with liver disease

Presencia del marcador lmp-1 del virus epstein barr en linfomas de caninos

Contact Info

Product

Resources

About